<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01658852</url>
  </required_header>
  <id_info>
    <org_study_id>Gastrectomy-MDZ-001</org_study_id>
    <nct_id>NCT01658852</nct_id>
  </id_info>
  <brief_title>Effects and Safety of Metronidazole in Patients With Gastrectomy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <brief_summary>
    <textblock>
      Recent study showed that SIBO is common among postgastrectomy patients and It appears to be&#xD;
      associated with postprandial intestinal symptoms and might aggravate late hypoglycemia. SIBO&#xD;
      could be a new therapeutic target for managing intestinal symptoms in postgastrectomy&#xD;
      patients.The purpose of this study is to determine whether antiboitic (metronidazole) is&#xD;
      effective in patients with postgasrectomy syndrome&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Because of difficulties on recruiting participants&#xD;
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient's Global Assessment of abdominal symptom</measure>
    <time_frame>4 week</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Post Gastrectomy State</condition>
  <arm_group>
    <arm_group_label>Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active drug: metronidazole 500mg three time per day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo three times per day for 10days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole</intervention_name>
    <arm_group_label>Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 70&#xD;
&#xD;
          -  gastrectomy for early gastric cancer with complete resection&#xD;
&#xD;
          -  no reccurrence after follow up more than 6 months&#xD;
&#xD;
          -  identified small bowel bacterial overgrowth by hydrogen breath test&#xD;
&#xD;
          -  symptoms of postgastrectomy syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypersensive to metronidazole&#xD;
&#xD;
          -  systemic chemotherapy history&#xD;
&#xD;
          -  other organic gastrointestinal disease (inflammatory bowel disease, carcinoid&#xD;
             syndrome, amyloidosis, intestinal obstruction)&#xD;
&#xD;
          -  other gastrointestinal operation history except appendectomy, cholecystectomy)&#xD;
&#xD;
          -  recent colonoscopic examination (within 30 days)&#xD;
&#xD;
          -  uncontrolled psychopathy&#xD;
&#xD;
          -  drug or alcohol abuser&#xD;
&#xD;
          -  pregnant or breast feeding woman&#xD;
&#xD;
          -  recent history of antibiotics treatment (within 90 days)&#xD;
&#xD;
          -  recent history of PPI or H2 blocker treatment (within 30 dyas)&#xD;
&#xD;
          -  recent history of probiotics treatment (within 30 dyas)&#xD;
&#xD;
          -  recent history of prokinetics or antispasmotic treatment (within 15 days)&#xD;
&#xD;
          -  severe systemic illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 3, 2012</study_first_submitted>
  <study_first_submitted_qc>August 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2012</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Myung-gui Choi</investigator_full_name>
    <investigator_title>prof.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

